FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment...
